Clinical trial NCT06960967: Effects of Chestnuts on Postprandial Glycaemic Response
Official title: Postprandial Effects of Chestnuts on Glycaemic Response: a Cross-over Trial in Healthy Adults
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Postprandial Glycemia
Insulin Resistance
Keywords: chestnuts
postprandial glycemia
postprandial insulinemia
glucose tolerance
Lead sponsor: Monash University
Sponsor class: OTHER
First posted: 2025-05-07
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: The participants will be requested to attend 2 morning visits to the research centre to receive one of the test meals. These meals will be isocaloric with or without the addition of chestnut flour. The order in which they undertake the two test visits will be randomised.
Primary purpose: OTHER

Brief summary: Nut consumption is known to improve health outcomes, such as reducing the risk of chronic diseases like diabetes, cognitive impairment, and cardiovascular diseases. While most research has focused on walnuts and almonds, there is limited information on the health benefits of chestnuts. Chestnuts are unique among tree nuts due to their high starch and fibre content, along with vitamins E and C, minerals (potassium, phosphorus, magnesium), and polyphenols.

Evidence from in vitro and animal studies suggests that chestnuts may positively affect health by regulating the gut microbiome, lowering the glycaemic index, and providing antioxidant benefits. The food industry is also exploring new uses for chestnuts, particularly in gluten-free products, due to their nutritional benefits and good taste. Nonetheless, no research has investigated the health effects of chestnuts in humans. By addressing this gap in the literature, the study may lead to the development of new dietary strategies for improved health outcomes.


Eligibility criteria: Inclusion Criteria:

* Adults 18-65 years old
* Available to attend two testing sessions at the research facility

Exclusion Criteria:

* Allergy to nuts and/or gluten,
* BMI\<18.5 or ≥30 kg/m2,
* Fasting glucose \>5.6 mmol/L, presence of diabetes and/or taking anti-diabetic medication
* Serious health conditions that may affect participation e.g. liver or thyroid dysfunction, recent major surgery,
* Smoker,
* Cardiovascular disease
* Pregnant or breastfeeding women
* Presence of implanted cardiac defibrillator

Primary outcomes:
measure: Postprandial blood glucose incremental area under the curve (iAUC)
timeFrame: Three hour blood glucose iAUC will be calculated from nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
measure: Postprandial plasma insulin incremental area under the curve (iAUC)
timeFrame: Three hour insulin iAUC will be calculated from seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
Secondary outcomes:
measure: Postprandial glucose concentration
timeFrame: Glucose concentration will be measured at nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
measure: Postprandial insulin concentration
timeFrame: Insulin concentration will be measured in finger prick blood samples at seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal.
measure: Time to peak glucose
timeFrame: Three hours
Other outcomes:
Locations:
Study officials:
References: